 result treatment high intens brief durat chemotherapi poor prognosi non-hodgkin lymphoma novel chemotherapeut approach treatment intermedi high-grad histolog non-hodgkin lymphoma subtransplant chemotherapi frequent interv inpati set initi evalu regimen poor prognosi patient project long-term surviv rate respons standard therapi march may untreat patient studi patient high-grad histolog patient larg cell lymphoma patient median age year rang year poor prognosi featur stage IV poor perform statu eastern cooper oncolog group scale multipl site diseas lactic dehydrogenas iu/l cm tumor mass patient shipp categori studi chemotherapi regimen attempt efficaci toxic patient cours therapi cyclophosphamid IV day IV day day doxorubicin IV day vincristin IV day IV day IV day hour leucovorin IV hour dose day complet respons CR rate confid interv ten relaps month follow-up overal event-fre surviv ef confid interv median follow-up month eleven patient small noncleav lymphoma CR actuari ef subgroup myelosuppress patient sever leukopenia median day rang day toxic death patient confid interv intens approach respons surviv poor risk non-hodgkin lymphoma patient